Abstracts Book - IMRC 2018

• SA1-P050
GRAPHENE OXIDE SUPPORTED STAR-LIKE GOLD
NANOPARTICLES AS SERS SUBSTRATE FOR LABEL-FREE
THERAPEUTIC DRUG MONITORING OF PACLITAXEL AND
CYCLOPHOSPHAMIDE IN BLOOD PLASMA
Sandeep Panikar 1,2 , Elder de la Rosa Cruz 3 , Tanya Amanda Camacho 1
1
Cátedra CONACYT-CIATEJ, Biomedical and Pharmaceutics, Mexico. 2 Centro de Investigaciones
en Optica, Nanophotonics and Advanced Material Group, Mexico. 3 Centro de Investigaciones
en Optica, Nanophotonics and Advanced Materials Group, Mexico.
This work represents the fabrication of substrates for Surface Enhanced
Raman Spectroscopy (SERS) using layer by layer (LbL) approach. The amino
modified star-like nanoparticles were attached to carboxyl groups of graphene
oxide by covalent linkage using NHS-EDC chemistry for better distribution. This
sequentially forms the hotspot like configuration on the edge of graphene oxide
due to the presence of more epoxy groups, thus creating ultrasensitive platform
for SERS detection. The presence of functional groups for LbL based fabrication
was confirmed by FTIR spectra, which is an important criterion for the
attachment of SERS components on substrates for enhanced stability and
substrates-to-substrates signal uniformity. The possible SERS detection has
been demonstrated using Crystal violet as Raman probe molecule on graphene
oxide, star-like nanoparticles and star-like nanoparticles attached to graphene
oxide (i.e., AuNPs@GO hybrid) by LbL approach with a detection limit of 1 x 10 -6
M, 1 x 10 -7 M and 1 x 10 -11 M respectively. The enhancement factor of 10 +7 was
achieved on AuNPs@GO hybrid compared to GO alone, as a result of
synchronization of chemical enhancement of graphene oxide and
electromagnetic enhancement of star-like nanoparticles. The SERS spectra can
be acquired within 20 seconds with a detection limit of 1 x 10 -9 M and 1 x 10 -10
M for Paclitaxel and Cyclophosphamide in blood plasma respectively, for labelfree
therapeutic drug monitoring (TDM). However, which is far rapid and
sensitive compared to currently available sophisticated analytical techniques
which involve high cost per test and time. This work shows the promise of
applying AuNPs@GO hybrid SERS substrate in a clinical setting for label-free
TDM and would help to reduce the undesirable side effects of chemotherapy as
an option for individualized treatment.